Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2010, Article ID 708931, 8 pages
http://dx.doi.org/10.4061/2010/708931
Review Article

Revisiting Estrogen: Efficacy and Safety for Postmenopausal Bone Health

Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, ON, Canada M5S 3E2

Received 1 February 2010; Accepted 26 April 2010

Academic Editor: Annie Kung

Copyright © 2010 Sandra M. Sacco and Wendy E. Ward. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Klibanski, L. Adams-Campbell, T. Bassford et al., “Osteoporosis prevention, diagnosis, and therapy,” Journal of the American Medical Association, vol. 285, no. 6, pp. 785–795, 2001. View at Google Scholar · View at Scopus
  2. January 2010, http://www.osteoporosis.ca/.
  3. R. Burge, B. Dawson-Hughes, D. H. Solomon, J. B. Wong, A. King, and A. Tosteson, “Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025,” Journal of Bone and Mineral Research, vol. 22, no. 3, pp. 465–475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Bagur, B. Oliveri, C. Mautalen et al., “Low levels of endogenous estradiol protect bone mineral density in young postmenopausal women,” Climacteric, vol. 7, no. 2, pp. 181–188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. S. R. Cummings, W. S. Browner, D. Bauer et al., “Endogenous hormones and the risk of hip and vertebral fractures among older women,” New England Journal of Medicine, vol. 339, no. 11, pp. 733–738, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. Huang, B. Ettinger, E. Vittinghoff, K. E. Ensrud, K. C. Johnson, and S. R. Cummings, “Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women,” Journal of Bone and Mineral Research, vol. 22, no. 11, pp. 1791–1797, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Ongphiphadhanakul, S. Chanprasertyothin, L. Chailurkit, S. Chansirikarn, G. Puavilai, and R. Rajatanavin, “Differential associations of residual estradiol levels with bone mineral density and serum lipids in postmenopausal women with osteoporosis,” Maturitas, vol. 48, no. 3, pp. 193–196, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. The Writing Group for the PEPI Trial, “Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial,” Journal of the American Medical Association, vol. 276, no. 17, pp. 1389–1396, 1996. View at Google Scholar · View at Scopus
  9. Writing Group for the Women's Health Initiative Investigators, “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial,” Journal of the American Medical Association, vol. 288, no. 3, pp. 321–333, 2002. View at Google Scholar · View at Scopus
  10. Women's Health Initiative Steering Committee, “Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial,” Journal of the American Medical Association, vol. 291, no. 14, pp. 1701–1712, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Pasco, M. A. Kotowicz, M. J. Henry, K. M. Sanders, E. Seeman, and G. C. Nicholson, “Hormone therapy and risk of non-vertebral fracture: Geelong osteoporosis study,” Osteoporosis International, vol. 15, no. 6, pp. 434–438, 2004. View at Google Scholar · View at Scopus
  12. Y. A. Hundrup, O. Ekholm, S. Høidrup, M. Davidsen, and E. B. Obel, “Risk factors for hip fracture and a possible effect modification by hormone replacement therapy. The Danish Nurse Cohort Study,” European Journal of Epidemiology, vol. 20, no. 10, pp. 871–877, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Cordera and V. C. Jordan, “Steroid receptors and their role in the biology and control of breast cancer growth,” Seminars in Oncology, vol. 33, no. 6, pp. 631–641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J.S. Lewis-Wambi and V. C. Jordan, “Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?” Breast Cancer Research, vol. 11, no. 3, p. 206, 2009. View at Google Scholar
  15. C. Punyadeera, P. Verbost, and P. Groothuis, “Oestrogen and progestin responses in human endometrium,” Journal of Steroid Biochemistry and Molecular Biology, vol. 84, no. 4, pp. 393–410, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Grodstein, J. E. Manson, G. A. Colditz, W. C. Willett, F. E. Speizer, and M. J. Stampfer, “A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease,” Annals of Internal Medicine, vol. 133, no. 12, pp. 933–941, 2000. View at Google Scholar · View at Scopus
  17. M. J. Stampfer, G. A. Colditz, W. C. Willett et al., “Postmenopausal estrogen therapy and cardiovascular disease—ten-year follow-up from the Nurses' Health Study,” New England Journal of Medicine, vol. 325, no. 11, pp. 756–762, 1991. View at Google Scholar · View at Scopus
  18. S. Hulley, D. Grady, T. Bush et al., “Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women,” Journal of the American Medical Association, vol. 280, no. 7, pp. 605–613, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. J. F. Farley, S. J. Blalock, and R. R. Cline, “Effect of the women's health initiative on prescription anti-osteoporosis medication utilization,” Osteoporosis International, vol. 19, no. 11, pp. 1603–1612, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Banks, V. Beral, G. Reeves, A. Balkwill, and I. Barnes, “Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women,” Journal of the American Medical Association, vol. 291, no. 18, pp. 2212–2220, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. E. Rossouw, R. L. Prentice, J. E. Manson et al., “Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause,” Journal of the American Medical Association, vol. 297, no. 13, pp. 1465–1477, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. W. H. Utian, D. F. Archer, G. A. Bachmann et al., “Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society,” Menopause, vol. 15, no. 4, pp. 584–602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. North American Menopause Society, “Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society,” Menopause, vol. 17, no. 2, pp. 242–255, 2010. View at Google Scholar
  24. A. Pines, D. W. Sturdee, M. H. Birkhauser et al., “HRT in the early menopause: scientific evidence and common perceptions,” Climacteric, vol. 11, no. 4, pp. 267–272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. M. Harman, E. A. Brinton, M. Cedars et al., “KEEPS: The Kronos Early Estrogen Prevention Study,” Climacteric, vol. 8, no. 1, pp. 3–12, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. A. L. Hersh, M. L. Stefanick, and R. S. Stafford, “National use of postmenopausal hormone therapy: annual trends and response to recent evidence,” Journal of the American Medical Association, vol. 291, no. 1, pp. 47–53, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. D. K. Wysowski, L. Golden, and L. Burke, “Use of menopausal estrogens and medroxyprogesterone in the United States, 1982–1992,” Obstetrics and Gynecology, vol. 85, no. 1, pp. 6–10, 1995. View at Publisher · View at Google Scholar · View at Scopus
  28. S. R. Davis, I. Dinatale, L. Rivera-Woll, and S. Davison, “Postmenopausal hormone therapy: from monkey glands to transdermal patches,” Journal of Endocrinology, vol. 185, no. 2, pp. 207–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Gambacciani and A. R. Genazzani, “Hormone replacement therapy: the benefits in tailoring the regimen and dose,” Maturitas, vol. 40, no. 3, pp. 195–201, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. M. R. Vickers, A. H. MacLennan, B. Lawton et al., “Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women,” British Medical Journal, vol. 335, no. 7613, pp. 239–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Cauley, D. G. Seeley, K. Ensrud, B. Ettinger, D. Black, and S. R. Cummings, “Estrogen replacement therapy and fractures in older women,” Annals of Internal Medicine, vol. 122, no. 1, pp. 9–16, 1995. View at Google Scholar
  32. L. Huot, C. M. Couris, V. Tainturier, S. Jaglal, C. Colin, and A.-M. Schott, “Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study,” Osteoporosis International, vol. 19, no. 7, pp. 1047–1054, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. J.-Å. Gustafsson, “Estrogen receptor β—a new dimension in estrogen mechanism of action,” Journal of Endocrinology, vol. 163, no. 3, pp. 379–383, 1999. View at Google Scholar · View at Scopus
  34. R. Wilson, Feminine Forever, M. Evans and Company, New York, NY, USA, 1966.
  35. J. Ness, W. S. Aronow, E. Newkirk, and D. McDanel, “Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative trial,” Journals of Gerontology. Series A, vol. 60, no. 4, pp. 460–462, 2005. View at Google Scholar · View at Scopus
  36. R. P. Heaney, “Design considerations for clinical investigations of osteoporosis,” in Osteoporosis, R. Marcus, D. Feldman, D. A. Nelson, and C. J. Rosen, Eds., pp. 1597–1620, Elsevier Academic Press, Burlington, Mass, USA, 3rd edition, 2008. View at Google Scholar
  37. H. N. Hodis and W. J. Mack, “Coronary heart disease and hormone replacement therapy after the menopause,” Climacteric, vol. 12, supplement 1, pp. 71–75, 2009. View at Google Scholar · View at Scopus
  38. J. E. Manson, M. A. Allison, J. E. Rossouw et al., “Estrogen therapy and coronary-artery calcification,” New England Journal of Medicine, vol. 356, no. 25, pp. 2591–2602, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Ettinger, K. E. Ensrud, R. Wallace et al., “Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial,” Obstetrics and Gynecology, vol. 104, no. 3, pp. 443–451, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Lindsay, C. Gallagher, M. Kleerekoper, and J. H. Pickar, “Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women,” Journal of the American Medical Association, vol. 287, no. 20, pp. 2668–2676, 2002. View at Google Scholar · View at Scopus
  41. M. Gambacciani, B. Cappagli, M. Ciaponi, A. Pepe, F. Vacca, and A. R. Genazzani, “Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women,” Maturitas, vol. 59, no. 1, pp. 2–6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. García-Pérez, J. Moreno-Mercer, J. Tarín, and A. Cano, “Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women,” Gynecological Endocrinology, vol. 22, no. 4, pp. 179–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Gambacciani, M. Ciaponi, B. Cappagli, and A. R. Genazzani, “Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women,” American Journal of Obstetrics and Gynecology, vol. 185, no. 5, pp. 1180–1185, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. R. R. Recker, K. M. Davies, R. M. Dowd, and R. P. Heaney, “The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial,” Annals of Internal Medicine, vol. 130, no. 11, pp. 897–904, 1999. View at Google Scholar · View at Scopus
  45. M. Schaefers, C. Muysers, P. Alexandersen, and C. Christiansen, “Effect of microdose transdermal 17β-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial,” Menopause, vol. 16, no. 3, pp. 559–565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. K. M. Prestwood, A. M. Kenny, A. Kleppinger, and M. Kulldorff, “Ultralow-dose micronized 17β-estradiol and bone density and bone metabolism in older women: a randomized controlled trial,” Journal of the American Medical Association, vol. 290, no. 8, pp. 1042–1048, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Notelovitz, V. A. John, and W. R. Good, “Effectiveness of Alora estradiol matrix transdermal delivery system in improving lumbar bone mineral density in healthy, postmenopausal women,” Menopause, vol. 9, no. 5, pp. 343–353, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. L. P. Shulman and D. Harari, “Low-dose transdermal estradiol for symptomatic perimenopause,” Menopause, vol. 11, no. 1, pp. 34–39, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Peeyananjarassri and R. Baber, “Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials,” Climacteric, vol. 8, no. 1, pp. 13–23, 2005. View at Publisher · View at Google Scholar · View at Scopus
  50. D. Grady, E. Vittinghoff, F. Lin et al., “Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women,” Menopause, vol. 14, no. 3, pp. 391–396, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Nielsen, J. Raundahl, P. C. Pettersen et al., “Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene,” Menopause, vol. 16, no. 4, pp. 785–791, 2009. View at Publisher · View at Google Scholar · View at Scopus